UroGen Pharma (URGN) Other Accumulated Expenses (2017 - 2026)

UroGen Pharma (URGN) has 10 years of Other Accumulated Expenses data on file, last reported at $5.5 million in Q1 2026.

• Quarterly Other Accumulated Expenses rose 15.73% year-over-year to $5.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.5 million (up 15.73% YoY) and the FY2025 annual result came in at $5.2 million, down 34.76% from the prior year.
• Other Accumulated Expenses climbed to $5.5 million in Q1 2026, from $5.2 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $7.9 million in Q4 2024 to a low of $3.0 million in Q2 2022.
• A 5-year average of $4.2 million and a median of $3.9 million in 2023 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Other Accumulated Expenses jumped 131.07% — and 2025, when it plunged 34.76%.
• Tracing URGN's Other Accumulated Expenses over 5 years: stood at $3.3 million in 2022, then grew by 17.83% to $3.9 million in 2023, then jumped by 105.91% to $7.9 million in 2024, then tumbled by 34.76% to $5.2 million in 2025, then increased by 5.15% to $5.5 million in 2026.
• The last three Other Accumulated Expenses figures came in at $5.5 million (Q1 2026), $5.2 million (Q4 2025), and $5.0 million (Q3 2025), per Business Quant data.